Ambry Genetics introduced The Ambry X-Linked Mental Retardation SuperPANEL™, a suite of genetic tests expected to pinpoint the cause of intellectual disability and X-linked mental retardation (XLMR).
This panel marks the first time next generation sequencing technology, coupled with microarrays, Sanger sequencing and traditional Fragile X testing, is being made clinically available to address this disorder, giving physicians a full range of reflex options to suit the needs of their patients.
The Ambry XLMR SuperPANEL spans all levels of genetic resolution, from genome-wide scan through focused study of the X chromosome to base-pair analysis of approximately ninety specific target genes. Components include the XLMR Array Plus(TM), the XLMR Next Gen Sequencing Panel, and individual sequencing tests including Fragile X. Testing can be customized for individual patients. The Sequencing Panel uses new and innovative technologies, including RainDance Technologies’ RDT 1000 system for sequence enrichment with the Illumina Genome Analyzer IIx. Ambry has been an Illumina Certified Service Provider for research services since 2007.
"Ambry Genetics is ideally suited to bring multigenic assays into the marketplace," said Charles Dunlop, Chief Executive Officer. "We’ve not only been performing services on these platforms for years with a very good understanding of the nuances of these technologies, but we also have over a decade of experience launching high information-content sequencing tests. We know how to deal with the interpretation issues that arise at the patient level, and our company is geared towards helping physicians with this type of information."
Source: Ambry Genetics
